Compare DraftKings Inc (DKNG) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Eli Lilly And Co — how do they compare? DraftKings Inc trades at $19.58 (market cap $9.86B), while Eli Lilly And Co trades at $1,163.51 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 105.5× DraftKings Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Eli Lilly And Co for 93 Days on average.
| DKNG | LLY | |
|---|---|---|
Market Cap | $9.86B | $1.04T |
Volume | 16,584,596 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $1.28K |
52-Week Low | $18.59 | $799.57 |
Typical Hold Time | 55 Days | 93 Days |
Enterprise Value | $10.80B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.15, down 3.04% and near its 52-week low of $18.95. The stock is technically bearish with weak moving averages, though RSI indicates potential oversold conditions. Fundamentally, revenue grew to $6.05B in 2025 with a slight net profit of $3.71M, but recent quarters show earnings misses. The company is investing in prediction markets and maintains a $1B EBITDA target for 2026.
Despite a high valuation (P/E 246.33) and recent price decline, 75% of analysts rate DKNG a Buy with a $33.13 consensus target. Key risks include competitive pressure, regulatory uncertainty, and the stock's sensitivity to growth expectations. The path to sustained profitability and margin expansion remains critical for investor confidence.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
